Literature DB >> 12898573

The association of the D2S2944 124 bp allele with recurrent early onset major depressive disorder in women.

Robert Philibert1, Kristin Caspers, Douglas Langbehn, Edward P Troughton, Rebecca Yucuis, Harinder K Sandhu, Remi J Cadoret.   

Abstract

Major depressive disorder (MDD) and substance use disorders (SUD) are complex behavioral disorders with 40-50% heritability. Recently, Zubenko and colleagues reported that the 124 bp allele of D2S2944, a tetranucleotide repeat marker on 2q35, is strongly associated with recurrent, early onset MDD (RE-MDD) and alcohol use disorders in women. To test this hypothesis, we examined the association of the 124 bp allele in a subset of 171 adoptees from the Iowa Adoption Studies, a population with high rates of MDD and SUD. We report that in our population, the 124 bp allele significantly associated with RE-MDD in women. There was slight evidence of an increased of SUD in women with the 124 bp allele with the rate of cannabis use disorders reaching statistical significance (P < 0.04) before correction for multiple comparisons. Given the history of prior studies implicating 2q35 as a locus encoding vulnerability to co-morbid alcoholism and depression, these findings strongly suggest that sequence variation conveying increased susceptibility to MDD and possibly SUD is in close proximity to D2S2944. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12898573     DOI: 10.1002/ajmg.b.20062

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  8 in total

Review 1.  Risk for recurrence in depression.

Authors:  Stephanie L Burcusa; William G Iacono
Journal:  Clin Psychol Rev       Date:  2007-03-03

2.  Replacement of homologous mouse DNA sequence with pathogenic 6-base human CREB1 promoter sequence creates murine model of major depressive disorder.

Authors:  George S Zubenko; Hugh B Hughes
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2011-05-19       Impact factor: 3.568

3.  Genetic markers of comorbid depression and alcoholism in women.

Authors:  Daniela O Procopio; Laura M Saba; Henriette Walter; Otto Lesch; Katrin Skala; Golda Schlaff; Lauren Vanderlinden; Peter Clapp; Paula L Hoffman; Boris Tabakoff
Journal:  Alcohol Clin Exp Res       Date:  2012-12-27       Impact factor: 3.455

4.  Effects of the A(-115)G variant on CREB1 promoter activity in two brain cell lines: Interactions with gonadal steroids.

Authors:  George S Zubenko; Hugh B Hughes
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-10-18       Impact factor: 3.568

5.  Genetic linkage of region containing the CREB1 gene to depressive disorders in families with recurrent, early-onset, major depression: a re-analysis and confirmation of sex-specific effect.

Authors:  Brion S Maher; Hugh B Hughes; Wendy N Zubenko; George S Zubenko
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-01-05       Impact factor: 3.568

6.  Linkage scan for quantitative traits identifies new regions of interest for substance dependence in the Collaborative Study on the Genetics of Alcoholism (COGA) sample.

Authors:  Arpana Agrawal; Anthony L Hinrichs; Gerald Dunn; Sarah Bertelsen; Danielle M Dick; Scott F Saccone; Nancy L Saccone; Richard A Grucza; Jen C Wang; C Robert Cloninger; Howard J Edenberg; Tatiana Foroud; Victor Hesselbrock; John Kramer; Kathleen K Bucholz; Samuel Kuperman; John I Nurnberger; Bernice Porjesz; Marc A Schuckit; Alison M Goate; Laura J Bierut
Journal:  Drug Alcohol Depend       Date:  2007-10-17       Impact factor: 4.492

Review 7.  Genetic variation and shared biological susceptibility underlying comorbidity in neuropsychiatry.

Authors:  Tomas Palomo; Richard M Kostrzewa; Richard J Beninger; Trevor Archer
Journal:  Neurotox Res       Date:  2007-07       Impact factor: 3.911

8.  Effects of the G(-656)A variant on CREB1 promoter activity in a neuronal cell line: interactions with gonadal steroids and stress.

Authors:  G S Zubenko; H B Hughes
Journal:  Mol Psychiatry       Date:  2008-03-04       Impact factor: 15.992

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.